Work

Development of a long-acting unbiased GIP receptor agonist for studies of GIP’s role in bone metabolism

Year: 2025

Type: article

Abstract: injections. In conclusion, the long-acting, unbiased compound 3 (hGIP(1-30-Cex)/Aib2/C16-diacid moiety in position 17), with retained activity for the human and rat GIPR, is suitable for bone remodeling studies in rats; hence, a useful tool compound for future research of GIP's therapeutic potential in bone-related diseases.

Source: Biochemical Pharmacology

DOI: 10.1016/j.bcp.2025.116893

Authors: Esther Karen Tordrup, Sarina Gadgaard, Johanne Windeløv, Jens Juul Holst, Lærke Smidt Gasbjerg, Bolette Hartmann, Mette Marie Rosenkilde

Institutions: University of Copenhagen, Novo Nordisk Foundation Center for Basic Metabolic Research

Language: English

Topic: Bone Metabolism and Diseases

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $3,590

Funders: Innovationsfonden, Novo Nordisk, Kirsten og Freddy Johansens Fond, Novo Nordisk Fonden

Awards: G2164084890, G3199460281, G419571993, G4892327378, G6189276268, G6846082730, G7513094091, G7548833942

OpenAlex ID: W4408750037

FWCI: 1.764

Cites: 76

Cited by: 7

Related to: 10